Drugs that contain Hydrocodone Bitartrate
1. Hysingla Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8529948 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 3 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(5 months ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(5 months ago) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(10 days ago) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(10 days ago) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
HYSINGLA ER family patents
2. Vantrela Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216176 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US9572803 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US8445018 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Jul, 2029
(5 years from now) | |
Market Authorisation Date: 17 January, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
VANTRELA ER family patents
3. Zohydro Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265760 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9339499 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9433619 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9421200 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9610286 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9333201 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10028946 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10456393 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10722511 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10322120 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9326982 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9486451 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US10092559 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US9452163 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US9132096 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US9713611 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain in patients with hepatic impairment; Treatment of pain
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER family patents